Can anyone tell me how in the world BPAX will be able to file Libigel NDA application without meeting primary or secondary efficacy end points? Safety is importtant but without efficacy I am not sure. I am not a basher but I havn't heard product approved just based on safety without efficacy.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.